MERCK Kommanditgesellschaft auf Aktien (MKGAF) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the MERCK Kommanditgesellschaft auf Aktien stock forecast from 0 analysts, the average analyst target price for MERCK Kommanditgesellschaft auf Aktien is not available over the next 12 months. MERCK Kommanditgesellschaft auf Aktien’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of MERCK Kommanditgesellschaft auf Aktien is Neutral, which is based on 7 positive signals and 8 negative signals. At the last closing, MERCK Kommanditgesellschaft auf Aktien’s stock price was USD 145.36. MERCK Kommanditgesellschaft auf Aktien’s stock price has changed by +0.07% over the past week, +1.15% over the past month and -15.49% over the last year.
No recent analyst target price found for MERCK Kommanditgesellschaft auf Aktien
No recent average analyst rating found for MERCK Kommanditgesellschaft auf Aktien
Company Overview MERCK Kommanditgesellschaft auf Aktien
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA. Read Less
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as w...Read More
Frequently Asked Questions About MERCK Kommanditgesellschaft auf Aktien (MKGAF) Stock
Stock Target Advisor's fundamental analysis for MERCK Kommanditgesellschaft auf Aktien's stock is Neutral.
MKGAF stock's dividend yield is 1.57%.
Our analysis grades MKGAF stock's dividend yield at F. This means that MKGAF stock's dividend yield is above 35% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this MKGAF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on MKGAF's stock to indicate what its average analyst target is.
MKGAF stock's Price/Earning ratio is 22.38.
Our analysis grades MKGAF stock's Price / Earning ratio at F. This means that MKGAF stock's Price/Earning ratio is above 68% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this MKGAF may be a overvalued for its sector.
The last closing price of MKGAF's stock was USD 145.36.
The most recent market capitalization for MKGAF is USD 61.66B.
Unfortunately we do not have enough analyst data on MKGAF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MERCK Kommanditgesellschaft auf Aktien's stock.
As per our most recent records MERCK Kommanditgesellschaft auf Aktien has 62,255 Employees.
MERCK Kommanditgesellschaft auf Aktien's registered address is Frankfurter Strasse 250, Darmstadt, Germany, 64293.
You can get more information about it from MERCK Kommanditgesellschaft auf Aktien's website at https://www.merckgroup.com/en.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About MERCK Kommanditgesellschaft auf Aktien (MKGAF) Stock
Stock Target Advisor's fundamental analysis for MERCK Kommanditgesellschaft auf Aktien's stock is Neutral.
MKGAF stock's dividend yield is 1.57%.
Our analysis grades MKGAF stock's dividend yield at F. This means that MKGAF stock's dividend yield is above 35% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this MKGAF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on MKGAF's stock to indicate what its average analyst target is.
MKGAF stock's Price/Earning ratio is 22.38.
Our analysis grades MKGAF stock's Price / Earning ratio at F. This means that MKGAF stock's Price/Earning ratio is above 68% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this MKGAF may be a overvalued for its sector.
The last closing price of MKGAF's stock was USD 145.36.
The most recent market capitalization for MKGAF is USD 61.66B.
Unfortunately we do not have enough analyst data on MKGAF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MERCK Kommanditgesellschaft auf Aktien's stock.
As per our most recent records MERCK Kommanditgesellschaft auf Aktien has 62,255 Employees.
MERCK Kommanditgesellschaft auf Aktien's registered address is Frankfurter Strasse 250, Darmstadt, Germany, 64293.
You can get more information about it from MERCK Kommanditgesellschaft auf Aktien's website at https://www.merckgroup.com/en.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MKGAF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
